MedTrace Logo

Ferumoxytol-enhanced Magnetic Resonance Imaging

NCT06348524 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-08-07

No results posted yet for this study

Summary

There are no current alternatives to diagnostic contrast-requiring imaging for patients with an eGFR \<30mL/min due to the association of gadolinium-based imaging modalities to nephrogenic systemic fibrosis and iodinated contrast-induced kidney injury. Ferumoxytol-enhanced imaging may offer an alternative approach.

Conditions

Interventions

DRUG

Ferumoxytol injection

ferumoxytol will assess patency of coronary arteries

Sponsors & Collaborators

  • Transmed Solutions

    lead OTHER

Principal Investigators

  • Andrew M Siedlecki, MD · authorized representative

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-01
Primary Completion
2022-12-30
Completion
2022-12-30
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06348524 on ClinicalTrials.gov